{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:42:24Z","timestamp":1770907344422,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-2014-09-4915"],"award-info":[{"award-number":["IP-2014-09-4915"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J3-2534"],"award-info":[{"award-number":["J3-2534"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Snakebites are a relatively rare medical emergency in Europe. In more than half of the annual cases caused by Vipera ammodytes, Vipera berus, and Vipera aspis, immunotherapy with animal-derived antivenom is indicated. Among eight products recently identified as available against European medically relevant species, only Zagreb antivenom, Viperfav, and ViperaTAb have been used almost exclusively for decades. Zagreb antivenom comprises V. ammodytes-specific F(ab\u2032)2 fragments. Viperfav is a polyspecific preparation based on F(ab\u2032)2 fragments against V. aspis, V. berus, and V. ammodytes venoms. ViperaTAb contains Fab fragments against the venom of V. berus. In 2014 the production of Zagreb antivenom was discontinued. Additionally, in the period of 2017 to 2018 a shortage of Viperfav occurred. Due to a lack of the product indicated for the treatment of V. ammodytes bites, other antivenoms were implemented into clinical practice without comparative assessment of their eligibility. The aim of our work was to identify a high-quality antivenom that might ensure the successful treatment of V. ammodytes and V. berus bites at the preclinical level. Differentiation between bites from these two species is difficult and unreliable in clinical practice, so the availability of a unique antivenom applicable in the treatment of envenoming caused by both species would be the most advantageous for Southeastern Europe. Zagreb antivenom, Viperfav, and ViperaTAb, as well as Viper venom antitoxin for V. berus envenoming and the in-development Inoserp Europe, which was designed to treat envenoming caused by all medically important European snakes, were comparatively tested for the first time. Emphasis was placed on their physicochemical properties, primarily purity and aggregate content, as well as their in vivo protective efficacies. As Zagreb antivenom is no longer available on the European market, Viperfav is the highest-quality product currently available and the only antivenom whose neutralisation potency against V. ammodytes and V. berus venoms was above regulatory requirements.<\/jats:p>","DOI":"10.3390\/toxins13030211","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T02:51:48Z","timestamp":1615776708000},"page":"211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of Preclinical Properties of Several Available Antivenoms in the Search for Effective Treatment of Vipera ammodytes and Vipera berus Envenoming"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-7278","authenticated-orcid":false,"given":"Tihana","family":"Kurtovi\u0107","sequence":"first","affiliation":[{"name":"Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia"},{"name":"Centre of Excellence for Virus Immunology and Vaccines, CERVirVac, Rockefellerova 10, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Lang Balija","sequence":"additional","affiliation":[{"name":"Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia"},{"name":"Centre of Excellence for Virus Immunology and Vaccines, CERVirVac, Rockefellerova 10, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miran","family":"Brvar","sequence":"additional","affiliation":[{"name":"Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zalo\u0161ka Cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Centre for Clinical Physiology, Faculty of Medicine, University of Ljubljana, Zalo\u0161ka Cesta 4, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojca","family":"Dobaja Borak","sequence":"additional","affiliation":[{"name":"Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zalo\u0161ka Cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Mateljak Luka\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia"},{"name":"Centre of Excellence for Virus Immunology and Vaccines, CERVirVac, Rockefellerova 10, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-0997","authenticated-orcid":false,"given":"Beata","family":"Halassy","sequence":"additional","affiliation":[{"name":"Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia"},{"name":"Centre of Excellence for Virus Immunology and Vaccines, CERVirVac, Rockefellerova 10, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.toxicon.2011.10.008","article-title":"Epidemiology of snakebites in Europe: A systematic review of the literature","volume":"59","author":"Chippaux","year":"2012","journal-title":"Toxicon"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/15563650.2017.1300261","article-title":"Antivenom for European Vipera species envenoming","volume":"55","author":"Lamb","year":"2017","journal-title":"Clin. Toxicol."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2017). Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. Annex 5, World Health Organization. No. 964."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/15563650.2014.904046","article-title":"Neurotoxicity of European viperids in Italy: Pavia Poison Control Centre case series 2001\u20132011","volume":"52","author":"Lonati","year":"2014","journal-title":"Clin. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bmj.2.6028.153","article-title":"Adder bites in Britain","volume":"2","author":"Reid","year":"1976","journal-title":"Br. Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2796.1994.tb01032.x","article-title":"Antivenom treatment in Vipera berus envenoming-report of 30 cases","volume":"235","author":"Persson","year":"1994","journal-title":"J. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/15563650500394597","article-title":"A nationwide study of Vipera Berus bites during one year\u2014Epidemiology and morbidity of 231 cases","volume":"44","author":"Salmonson","year":"2006","journal-title":"Clin. Toxicol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11552-008-9114-2","article-title":"The management of pit viper envenomation of the hand","volume":"3","author":"Bozkurt","year":"2008","journal-title":"Hand"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"De Haro, L., Glaizal, M., Tichadou, L., Blanc-Brisset, I., and Hayek-Lanthois, M. (2009). Asp viper (Vipera aspis) envenomation: Experience of the Marseille Poison Centre from 1996 to 2008. Toxins, 1.","DOI":"10.3390\/toxins1020100"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/15563650.2012.660695","article-title":"European viper envenomings: Assessment of Viperfav\u2122 and other symptomatic treatments","volume":"50","author":"Boels","year":"2012","journal-title":"Clin. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxicon.2015.09.039","article-title":"European viper envenomation recorded by French poison control centers: A clinical assessment and management study","volume":"108","author":"Jollivet","year":"2015","journal-title":"Toxicon"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2796.1997.80896000.x","article-title":"First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming","volume":"241","author":"Persson","year":"1997","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.wem.2018.08.002","article-title":"Severe systemic envenomation following Vipera berus bite managed with ViperaTAb antivenom","volume":"30","author":"Hamilton","year":"2019","journal-title":"Wilderness Environ. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/15563650.2020.1726377","article-title":"Snake bites by European vipers in mainland France in 2017\u20132018: Comparison of two antivenoms Viperfav\u00ae and Viperatab\u00ae","volume":"58","author":"Boels","year":"2020","journal-title":"Clin. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15563650.2016.1277235","article-title":"Vipera ammodytes bites treated with antivenom ViperaTAb: A case series with pharmacokinetic evaluation","volume":"55","author":"Brvar","year":"2017","journal-title":"Clin. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Casewell, N.R., Al-Abdulla, I., Smith, D., Coxon, R., and Landon, J. (2014). Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins, 6.","DOI":"10.3390\/toxins6082471"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arredondo, A., Mart\u00ednez, M., Calder\u00f3n, A., Sald\u00edvar, A., and Soria, R. (2019). Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae. Toxins, 11.","DOI":"10.3390\/toxins11030149"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxicon.2018.06.084","article-title":"Current technology for the industrial manufacture of snake antivenoms","volume":"151","author":"Vargas","year":"2018","journal-title":"Toxicon"},{"key":"ref_19","unstructured":"European Directorate for the Quality of Medicines (2019). Viper venom antiserum, European (01\/2008:0145). European Pharmacopoeia, Council of Europe. [10th ed.]."},{"key":"ref_20","unstructured":"World Health Organization (WHO) (2021, January 15). Guidelines for the Management of Snake-Bites. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/204464."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0041-0101(92)90384-H","article-title":"An affinity purified ovine antivenom for the treatment of Vipera berus envenoming","volume":"30","author":"Smith","year":"1992","journal-title":"Toxicon"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/187152811797200605","article-title":"Immune response towards snake venoms","volume":"10","author":"Villalta","year":"2011","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biologicals.2012.11.001","article-title":"Assessment of snake antivenom purity by comparing physicochemical and immunochemical methods","volume":"41","author":"Segura","year":"2013","journal-title":"Biologicals"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez, J.M. (2018). Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories. Toxins, 11.","DOI":"10.3390\/toxins11010005"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0003-2697(73)90374-6","article-title":"Spectrophotometric determination of protein concentration in cell extracts containing tRNA\u2019s and rRNA\u2019s","volume":"54","author":"Ehresmann","year":"1973","journal-title":"Anal. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpba.2018.10.020","article-title":"Concept of sample-specific correction of immunoassay results for precise and accurate IgG quantification in horse plasma","volume":"164","author":"Halassy","year":"2017","journal-title":"J. Pharmaceut. Biomed."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/3\/211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:35:13Z","timestamp":1760160913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/3\/211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,13]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["toxins13030211"],"URL":"https:\/\/doi.org\/10.3390\/toxins13030211","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,13]]}}}